Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The Company's lead product candidate, Zilretta™ (FX006), is an extended release intra-articular, analgesic candidate in late-stage development for moderate to severe osteoarthritis pain.
Zilretta™ has received Fast Track Designation from the FDA. This designation is given to a drug in clinical development that is intended to treat a serious condition and addresses unmet medical need.
Net income (Q1, 2018)
EBIT (Q1, 2018)
Market capitalization (14-Jun-2018)
Closing share price (14-Jun-2018)
|USD||Q1, 2014||Q1, 2015||Q2, 2015||Q3, 2015||Q1, 2016||Q2, 2016||Q3, 2016||Q1, 2017||Q2, 2017||Q1, 2018|
|(6.5 m)||(9.2 m)||(21.6 m)||(11.1 m)||(16.8 m)||(14.2 m)||(17.8 m)||(23.9 m)||(52.8 m)||(41.6 m)|
Depreciation and Amortization
|27.3 k||39.7 k||82.4 k||927 k||563 k|
|671.8 k||592.8 k||(196.2 k)||1.9 m||3.1 m||3.5 m||2 m||2.2 m||736 k||(2.8 m)|